Nuformix plc (LON:NFX – Get Free Report)’s share price traded down 11.8% during trading on Wednesday . The company traded as low as GBX 0.13 and last traded at GBX 0.14. 27,570,943 shares changed hands during mid-day trading, a decline of 10% from the average daily volume of 30,772,732 shares. The stock had previously closed at GBX 0.16.
Nuformix Trading Down 11.8%
The firm has a market capitalization of £3.71 million, a price-to-earnings ratio of -4.85 and a beta of 1.54. The firm has a 50 day moving average price of GBX 0.17 and a two-hundred day moving average price of GBX 0.20.
Nuformix (LON:NFX – Get Free Report) last issued its earnings results on Thursday, May 28th. The company reported GBX (0.02) earnings per share (EPS) for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
See Also
- Five stocks we like better than Nuformix
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
- AMD’s Post-Earnings Drop May Be the Opportunity Investors Wanted
- 3 Stocks That Prove the AI Trade Isn’t Over, It Moved
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
